timothy sykes logo
CMPX Rises As Compass Therapeutics Sets Key Trial Webcast Thumbnail
G Google News

CMPX Rises As Compass Therapeutics Sets Key Trial Webcast

MATT MONACO•UPDATED APR. 26, 2026, 11:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Compass Therapeutics Inc. stocks have been trading up by 8.25 percent following bullish sentiment around its latest clinical trial progress.

What Traders Need To Know

  • Compass Therapeutics announced it will host an 2026/04/27 webcast to present topline secondary endpoint data from its Phase 2/3 COMPANION-002 trial of tovecimig plus paclitaxel in advanced biliary tract cancer.
  • The webcast will focus specifically on secondary endpoint results from the COMPANION-002 study evaluating tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer.
  • The COMPANION-002 trial is a Phase 2/3 study, indicating it is in a late stage of clinical development for the combination regimen of tovecimig and paclitaxel.
  • Recent weekly trading shows CMPX breaking higher from around $5.00 into the mid-$5s, signaling rising attention ahead of the webcast.
  • Intraday volatility with a sharp dip and strong rebound highlights active positioning by short-term traders into this catalyst.

Candlestick Chart

Weekly Update Apr 20 – Apr 24, 2026: On Sunday, April 26, 2026 Compass Therapeutics Inc. stock [NASDAQ: CMPX] is trending up by 8.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – neutral

Compass Therapeutics remains an early‑stage oncology platform with no commercial revenue and deeply negative profitability metrics (pretax margin ~‑33k%, ROE ~‑41%). The balance sheet is the key asset: ~$209M in cash and equivalents versus only ~$23M in total liabilities, a current ratio of ~15x, and minimal leverage (debt‑to‑equity 0.05). However, Q4 2025 operating cash burn of ~$13M and negative free cash flow of ~$13M underscore continued dependence on external capital over the medium term.

Weekly price action around $5.20–5.60 shows a nascent uptrend, with a sharp range expansion on 26‑04‑24 (low ~$5.03, high ~$5.85, close ~$5.64), implying aggressive dip‑buying and short‑covering into news. Intraday 5‑minute candles (not shown numerically but implied by the spike) likely featured elevated volume and repeated defenses near $5.20. The key actionable level is $5.20–5.25 as support; a sustained break below that zone would invalidate the current bullish swing.

The upcoming April 27, 2026 webcast on COMPANION‑002 secondary endpoints is the dominant near‑term catalyst and will likely drive event‑focused trading. Relative to broader Healthcare and Biotech benchmarks, Compass offers stronger cash backing but higher binary trial risk and no near‑term earnings leverage. With clear data‑readout risk, risk‑tolerant investors can accumulate above $5.20 support, targeting $6.25–6.50 near term; a break of $5.00 sets next support around $4.40. Overall outlook: cautiously constructive but data‑dependent.

More Breaking News

Quick Financial Overview

Compass Therapeutics Inc. sits in a classic high-risk biotech profile: meaningful cash, no commercial revenue in the data provided, and deep operating losses. The latest quarterly income statement shows a net loss of about $15.7M, or roughly -$0.08 per share, driven mainly by $13.7M in research and development and $4.3M in general and administrative expenses. For traders, that confirms the story is almost entirely about clinical progress and capital runway, not current earnings.

On the balance sheet side, Compass Therapeutics Inc. reported total assets near $219.6M and stockholders’ equity of about $196.8M, with long-term debt only around $8.8M. Cash, cash equivalents, and short-term investments total roughly $208.9M, while current liabilities sit near $14.0M, producing a very strong current ratio of about 15. That means CMPX is well-capitalized for near-term trial work, even though returns on equity and assets are sharply negative.

Cash flow data shows operating cash burn around $13.3M for the quarter, with free cash flow in the same range, offset by active management of short-term investments. From a trading standpoint, that burn rate looks manageable against the cash pile, but it still anchors CMPX as a pre-revenue, binary-catalyst name. On the chart, weekly prices moved from near $5.03 to about $5.64, and the intraday candle shows a drop under $5.00 followed by a rebound toward $5.03, reflecting dip buying and growing anticipation into the 2026/04/27 COMPANION-002 webcast.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”